Genetic Variability of Human Cytomegalovirus Clinical Isolates Correlates With Altered Expression of Natural Killer Cell-Activating Ligands and IFN-γ.
Cells, Cultured
Cytomegalovirus
/ genetics
Cytomegalovirus Infections
/ immunology
Cytotoxicity, Immunologic
/ genetics
GPI-Linked Proteins
/ genetics
Gene Expression
Genetic Variation
High-Throughput Nucleotide Sequencing
/ methods
Humans
Immune Evasion
/ genetics
Intercellular Signaling Peptides and Proteins
/ genetics
Interferon-gamma
/ immunology
Killer Cells, Natural
/ immunology
Ligands
Male
NK Cell Lectin-Like Receptor Subfamily K
/ genetics
Reverse Transcriptase Polymerase Chain Reaction
NK cells
congenital infection
genetic variability
human cytomegalovirus (HCMV)
immunomodulation
innate immunity
multiple-strain infection
next generation sequencing
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
04
02
2020
accepted:
23
03
2021
entrez:
26
4
2021
pubmed:
27
4
2021
medline:
29
6
2021
Statut:
epublish
Résumé
Human cytomegalovirus (HCMV) infection often leads to systemic disease in immunodeficient patients and congenitally infected children. Despite its clinical significance, the exact mechanisms contributing to HCMV pathogenesis and clinical outcomes have yet to be determined. One of such mechanisms involves HCMV-mediated NK cell immune response, which favors viral immune evasion by hindering NK cell-mediated cytolysis. This process appears to be dependent on the extent of HCMV genetic variation as high levels of variability in viral genes involved in immune escape have an impact on viral pathogenesis. However, the link between viral genome variations and their functional effects has so far remained elusive. Thus, here we sought to determine whether inter-host genetic variability of HCMV influences its ability to modulate NK cell responses to infection. For this purpose, five HCMV clinical isolates from a previously characterized cohort of pediatric patients with confirmed HCMV congenital infection were evaluated by next-generation sequencing (NGS) for genetic polymorphisms, phylogenetic relationships, and multiple-strain infection. We report variable levels of genetic characteristics among the selected clinical strains, with moderate variations in genome regions associated with modulation of NK cell functions. Remarkably, we show that different HCMV clinical strains differentially modulate the expression of several ligands for the NK cell-activating receptors NKG2D, DNAM-1/CD226, and NKp30. Specifically, the DNAM-1/CD226 ligand PVR/CD155 appears to be predominantly upregulated by fast-replicating ("aggressive") HCMV isolates. On the other hand, the NGK2D ligands ULBP2/5/6 are downregulated regardless of the strain used, while other NK cell ligands (i.e., MICA, MICB, ULBP3, Nectin-2/CD112, and B7-H6) are not significantly modulated. Furthermore, we show that IFN-γ; production by NK cells co-cultured with HCMV-infected fibroblasts is directly proportional to the aggressiveness of the HCMV clinical isolates employed. Interestingly, loss of NK cell-modulating genes directed against NK cell ligands appears to be a common feature among the "aggressive" HCMV strains, which also share several gene variants across their genomes. Overall, even though further studies based on a higher number of patients would offer a more definitive scenario, our findings provide novel mechanistic insights into the impact of HCMV genetic variability on NK cell-mediated immune responses.
Identifiants
pubmed: 33897679
doi: 10.3389/fimmu.2021.532484
pmc: PMC8062705
doi:
Substances chimiques
GPI-Linked Proteins
0
Intercellular Signaling Peptides and Proteins
0
Ligands
0
NK Cell Lectin-Like Receptor Subfamily K
0
ULBP2 protein, human
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
532484Informations de copyright
Copyright © 2021 Galitska, Coscia, Forni, Steinbrueck, De Meo, Biolatti, De Andrea, Cagliani, Leone, Bertino, Schulz, Santoni, Landolfo, Sironi, Cerboni and Dell’Oste.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Infect Dis. 2013 Mar;56(6):817-24
pubmed: 23196955
DNA Seq. 1991;2(1):33-8
pubmed: 1666312
Front Immunol. 2017 Apr 11;8:390
pubmed: 28443092
J Infect Dis. 2003 Mar 1;187(5):809-19
pubmed: 12599055
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):728-32
pubmed: 21187373
Nat Immunol. 2012 Feb 16;13(3):214-22
pubmed: 22344284
J Exp Med. 2003 Aug 18;198(4):557-67
pubmed: 12913096
J Leukoc Biol. 2002 Feb;71(2):173-83
pubmed: 11818437
J Immunol. 2004 Apr 1;172(7):3994-8
pubmed: 15034010
J Immunol. 2005 Dec 1;175(11):7457-65
pubmed: 16301653
Microbes Infect. 2018 Oct - Nov;20(9-10):543-551
pubmed: 29287989
Future Virol. 2012 Mar 1;7(3):279-293
pubmed: 23308079
J Virol. 2015 May 13;89(15):7673-7695
pubmed: 25972543
J Virol. 2015 Jul;89(14):7314-28
pubmed: 25948747
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14223-8
pubmed: 14623981
Cell Rep. 2015 Feb 17;10(6):968-982
pubmed: 25683719
Curr Top Microbiol Immunol. 2008;325:1-19
pubmed: 18637497
Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
J Gen Virol. 2010 Aug;91(Pt 8):2034-2039
pubmed: 20410314
Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12396-401
pubmed: 14519856
Virus Evol. 2016 Jun 15;2(1):vew017
pubmed: 30288299
Front Immunol. 2018 Oct 01;9:2214
pubmed: 30327650
Front Microbiol. 2014 May 19;5:218
pubmed: 24904534
Int J Mol Sci. 2019 Jul 24;20(15):
pubmed: 31344940
J Gen Virol. 2004 May;85(Pt 5):1301-1312
pubmed: 15105547
Med Microbiol Immunol. 2019 Aug;208(3-4):495-512
pubmed: 30805724
Mediators Inflamm. 2012;2012:607276
pubmed: 22701276
J Infect Dis. 2019 Jul 31;220(5):781-791
pubmed: 31050742
J Clin Virol. 2018 Nov;108:132-140
pubmed: 30312910
Lancet Infect Dis. 2017 Jun;17(6):e177-e188
pubmed: 28291720
Mol Biol Evol. 2006 Feb;23(2):254-67
pubmed: 16221896
J Gen Virol. 2009 Oct;90(Pt 10):2375-2380
pubmed: 19553388
J Virol. 2009 Dec;83(23):12046-56
pubmed: 19759126
J Immunol. 2013 Jul 15;191(2):828-36
pubmed: 23761635
J Clin Virol. 2017 Nov;96:32-36
pubmed: 28938230
EMBO J. 2006 Sep 20;25(18):4390-9
pubmed: 16932746
J Immunol. 2003 Jul 15;171(2):902-8
pubmed: 12847260
Front Microbiol. 2019 Oct 04;10:2297
pubmed: 31636622
J Virol. 2006 Jun;80(12):6003-12
pubmed: 16731939
Viruses. 2018 Aug 03;10(8):
pubmed: 30081449
J Pathol. 2015 Jan;235(2):288-97
pubmed: 25205255
J Virol. 2010 Jan;84(1):291-302
pubmed: 19846516
Viruses. 2019 Dec 28;12(1):
pubmed: 31905677
PLoS One. 2014 Sep 26;9(9):e108277
pubmed: 25259891
J Immunol. 2016 Nov 15;197(10):4066-4078
pubmed: 27733551
Proc Natl Acad Sci U S A. 2020 Jan 14;117(2):816-817
pubmed: 31874930
Vaccine. 2019 Nov 28;37(50):7437-7442
pubmed: 29622379
J Infect Dis. 2017 Jun 1;215(11):1673-1683
pubmed: 28368496
Int Immunol. 2015 Jan;27(1):11-20
pubmed: 25087232
PLoS Pathog. 2011 May;7(5):e1001344
pubmed: 21625576
Curr Opin Immunol. 2017 Feb;44:43-51
pubmed: 27984782
J Virol. 2004 May;78(9):4444-53
pubmed: 15078925
J Virol. 2002 May;76(10):4836-47
pubmed: 11967300
Rev Med Virol. 2001 May-Jun;11(3):191-200
pubmed: 11376481
J Gen Virol. 1999 Nov;80 ( Pt 11):2867-2877
pubmed: 10580048
Virus Genes. 2019 Apr;55(2):138-164
pubmed: 30604286
J Virol. 2009 Dec;83(23):12345-54
pubmed: 19793804
Transpl Infect Dis. 2012 Apr;14(2):132-40
pubmed: 22093996
J Immunol. 2018 Jun 15;200(12):3881-3889
pubmed: 29866770
Viruses. 2019 Oct 17;11(10):
pubmed: 31627371
PLoS Pathog. 2015 Apr 14;11(4):e1004811
pubmed: 25875600
J Gen Virol. 2010 Jun;91(Pt 6):1535-46
pubmed: 20479471
PLoS Pathog. 2013 Mar;9(3):e1003224
pubmed: 23555243
Immunity. 2017 Nov 21;47(5):820-833
pubmed: 29166586
PLoS Pathog. 2018 Jan 29;14(1):e1006867
pubmed: 29377960
Proc Natl Acad Sci U S A. 2020 Jan 14;117(2):818-819
pubmed: 31874929
Viruses. 2014 Mar 05;6(3):1049-72
pubmed: 24603756
Proc Natl Acad Sci U S A. 2019 Mar 19;116(12):5693-5698
pubmed: 30819890
J Virol. 2013 May;87(10):6005-19
pubmed: 23514890
J Virol. 2004 Sep;78(18):10023-33
pubmed: 15331735
Med Microbiol Immunol. 2015 Jun;204(3):273-84
pubmed: 25894764
Nat Immunol. 2005 Feb;6(2):181-8
pubmed: 15640804
Curr Opin Immunol. 2016 Apr;39:82-9
pubmed: 26845614
J Immunol. 2010 Jul 15;185(2):1093-102
pubmed: 20530255
PLoS Genet. 2013;9(9):e1003735
pubmed: 24086142
Pathogens. 2018 Jan 28;7(1):
pubmed: 29382090
Nat Rev Immunol. 2011 Feb;11(2):143-54
pubmed: 21267015
Science. 2012 Nov 23;338(6110):1088-93
pubmed: 23180859
J Virol. 1996 Jan;70(1):78-83
pubmed: 8523595
Viruses. 2019 Dec 23;12(1):
pubmed: 31878068
PLoS One. 2017 Feb 21;12(2):e0171959
pubmed: 28222150
Curr Opin Virol. 2019 Feb;34:130-139
pubmed: 30877885
Clin Microbiol Rev. 2013 Jan;26(1):86-102
pubmed: 23297260
Front Microbiol. 2015 Sep 24;6:1016
pubmed: 26441939
Front Immunol. 2018 Mar 12;9:476
pubmed: 29662484
J Virol. 2010 Sep;84(18):9472-86
pubmed: 20592073
NPJ Vaccines. 2018 Sep 20;3:38
pubmed: 30275984
Virol J. 2005 Feb 23;2:14
pubmed: 15727684
J Virol. 2018 Jun 29;92(14):
pubmed: 29720522
Sci Rep. 2017 Nov 22;7(1):15989
pubmed: 29167532
PLoS Pathog. 2014 May 01;10(5):e1004058
pubmed: 24787765
J Virol. 1999 Dec;73(12):10040-50
pubmed: 10559318
J Gen Virol. 2001 Jun;82(Pt 6):1429-1438
pubmed: 11369888
Annu Rev Immunol. 2013;31:227-58
pubmed: 23516982
Curr Opin Pediatr. 2016 Feb;28(1):81-5
pubmed: 26709686
Immunol Cell Biol. 2011 Feb;89(2):216-24
pubmed: 20567250